NanoViricides, Inc. (NNVC)
| Market Cap | 28.25M +23.9% |
| Revenue (ttm) | n/a |
| Net Income | -8.09M |
| EPS | -0.43 |
| Shares Out | 22.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,219 |
| Open | 1.260 |
| Previous Close | 1.280 |
| Day's Range | 1.220 - 1.276 |
| 52-Week Range | 0.850 - 2.230 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+383.87%) |
| Earnings Date | Sep 28, 2026 |
About NNVC
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company’s product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NNVC stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 383.87% from the latest price.
News
NanoViricides registers to sell 2.52M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.52M shares of common stock. The company is not selling any…
NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’
NanoViricides (NNVC), announced that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon…
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th...
NanoViricides receives regulatory approval for Phase II trial of NV-387
NanoViricides (NNVC) received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the…
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces t...
NanoViricides awaits regulatory approval to being Phase II trial of NV-387
The company said, “NanoViricides (NNVC) is eagerly awaiting regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies, after having filed an application to the local regulatory…
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that ...
NanoViricides prices $3.8M registered direct offering
NanoViricides (NNVC) entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock, together with accompan...
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectr...
NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial
NanoViricides (NNVC) has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus…
NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial
NanoViricides (NNVC) received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of...
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that ...
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a C...
NanoViricides initiated with an Outperform at Noble Capital
Noble Capital initiated coverage of NanoViricides (NNVC) with an Outperform rating and $6 price target NanoViricides has a proprietary technology platform that it has used to formulate antivirals with...
NanoViricides advances towards Phase II clinical trial of NV-387
NanoViricides (NNVC) updated that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for…
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it ...
NanoViricides granted Rare Pediatric Disease Drug designation for NV-387
NanoViricides (NNVC) announced that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted a “Rare Pediatric Disease Drug” Designation by the US FDA Office of Orphan Products Devel...
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of ...
NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo
NanoViricides (NNVC) shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of Monkeypox Treatment to the Democratic Republic of Congo, in preparation for enrollment of patients.
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical T...
NanoViricides files to sell 1.33M shares of common stock for holders
16:37 EDT NanoViricides (NNVC) files to sell 1.33M shares of common stock for holders
NanoViricides announces proposal approved by Pillar Committee in DRC
NNanoViricides (NNVC) announces that its proposal to perform a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus has been approved by the…
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides a...
NanoViricides proposes Phase II trial of NV-387 gummies in Ebola
NanoViricides (NNVC) has proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus to the Committee in Charge in the Democratic Republic…
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides an...